Clinical Trial Update: Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) Patients [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 study of TG01 in combination with erlotinib in non-small cell lung cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TG01
• Tarceva (erlotinib)

Snippet

Sponsor: Tragara Pharmaceuticals, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED